|Previous Section||Index||Home Page|
Mr. Lansley: To ask the Secretary of State for Health pursuant to the answer to the hon. Member for Portsmouth, South (Mr. Hancock) of 20 March 2006, Official Report, column 175W, on section 64, when the central budget review will be completed. 
Mr. Ivan Lewis: The central budget review for 2006-07 was completed at the end of April 2006. Final central budget allocations were issued to directors at the start of June. The allocations have been subject to minor reductions to cover a small number of pressures that were considered inescapable.
Mr. Walter: To ask the Secretary of State for Health how many dental laboratories there were in (a) England and (b) North Dorset in December 2005; and what estimate she has made of the number of dental laboratories which have closed in each area since this date. 
Ms Rosie Winterton: Between December 2005 and July 2006, the number of dental laboratories registered under the medical devices directive in the United Kingdom increased from 3,090 to 3,104. We do not have any more detailed information on numbers of laboratories, as dental laboratories are private enterprises with which the national health service has no contractual relationship.
Mr. Greg Knight: To ask the Secretary of State for Health what assessment she has made of the relative (a) efficiency and (b) effectiveness of (i) naltraczone, (ii) Subutex and (iii) methadone in treating drug addiction; whether such drugs are to be made more widely available; and if she will make a statement. 
The Department recognises the key role that effective pharmacotherapies, including substitute opiate prescribing and medications such as naltrexone to assist relapse prevention, may play in the management of opiate dependence. The Department published its evidence-based Clinical Guidelines, Drug misuse and dependenceguidelines on clinical management, in 1999, on the advice of an independent expert group and in conjunction with relevant professional bodies. The 1999 Clinical Guidelines address the use of methadone, buprenorphine (more recently with a marketing authorisation for use as Subutex) and naltrexone. The guidelines discuss the relative effectiveness of buprenorphine and methadone, but as naltrexone is licensed only for use to support relapse prevention, no direct comparison is feasible with the opiate substitute methadone and buprenorphine. The guidelines do support the use of all these drugs as potentially effective opiate misuse treatments when used
appropriately. The Departments clinical guidelines are due to be updated in 2006-07 and this will take into account planned guidance on the use of all these drugs due to be published in 2007 by the National Institute for Health and Clinical Excellence (NICE).
The Department of Health has asked NICE, within a package of work that they will be undertaking on drug treatment, to carry out a technology appraisal on oral methadone and sublingual buprenorphine as opiate substitute treatments. This appraisal will evaluate the clinical effectiveness and cost-effectiveness of these drugs as substitute opiates for the management of opiate misusers. The Department also asked at the same time for a similar technology appraisal for naltrexone as a treatment for relapse prevention for opiate misuse. This will include appraisal of its clinical effectiveness and cost-effectiveness. Both these technology appraisals are scheduled for publication in March 2007.
All three of these drugs are currently prescribed for management of opiate dependence. Given that the NHS are obliged to implement guidance produced by NICE, the outcome of their work on drug treatment will be an important support in enhancing the effectiveness of drug treatment and in particular substitute prescribing.
Andy Burnham [holding answer 5 July 2006]: Combating methicillin-resistant Staphylococcus aureus (MRSA) and other health care associated infections (HCAIs), continues to be a priority for Government. A target to reduce the number of MRSA bloodstream infections by half by April 2008 is in place and each trust has its own target. The total number of these infections in 2004-05 was 7,212, compared with 7,684 in 2003-04. Figures for 2005-06 will be published later this month.
All acute trusts have signed up to a Saving Lives package of best practice measures. The Department continues to engage those trusts facing the most significant challenges and it will seek to work with trusts most likely to benefit from support tailored to their organisational needs. Additionally, the Health Act, which received Royal Assent on 19 July, intends through the new code of practice, to give a statutory footing to what is already accepted as best practicethus driving up standards of hygiene and infection control.
Mr. Ivan Lewis: The most common cause of leg ulcers is poor circulation triggered by high blood pressure, diabetes, and coronary heart disease. Obesity and smoking are also known to increase the risk of leg ulcers.
The Departments preventive programme is aimed at the effective management of these underlying medical conditions through the quality and outcomes framework component of the new general medical services contract for general practices introduced in April 2004, as well as public health campaigns to raise awareness of the health risks associated with smoking and clinical obesity.
Mr. Amess: To ask the Secretary of State for Health what steps she plans to take to ensure that primary care trusts continue to provide specialist myalgic encephalomyelitis and encephalopathy services after their reconfiguration in October 2006; and if she will make a statement. 
Mr. Ivan Lewis: We have no plans to address specifically the provision of services for those living with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) during the forthcoming reconfiguration of primary care trusts (PCTs).
The reconfigured PCTs will be expected to provide the same level of health and social care provision as existing trusts. PCTs have the freedom to decide how best to provide health and social care for those with CFS/ME, either in existing services or in a specialist centre.
Mr. Harper: To ask the Secretary of State for Health which health service facilities in the geographical area covered by the new strategic health authority for the South West (a) she and (b) her Ministers plan to visit; and when. 
Mr. Ivan Lewis: My right hon. Friend the Secretary of State for Health plans to visit the geographical area covered by the new strategic health authority for the South West on 25 July 2006. She will visit a number of health facilities (yet to be confirmed) in Shepton Mallet, Cirencester and Bath. The Minister with responsibility for care services will also visit the area in September although specific details are yet to be arranged.
Mr. Lansley: To ask the Secretary of State for Health pursuant to the answer of 16 June 2006, Official Report, column 1558W, on the National Programme for Information Technology, what the total level of savings are which have been achieved by NHS organisations where national programme systems and services have been delivered ahead of time; and in which NHS organisations these savings were achieved. 
Caroline Flint: Comprehensive information of the kind requested is not collected centrally. However, the most obvious example of savings of the kind described is when new systems, paid for under the programme, have replaced systems that local national health service bodies have previously been paying for. Across the whole of the NHS, and over the 10-year life of the national programme, these savings will be very substantial. In the case of the local service provider contracts, local savings are expected to offset nearly half the local costs over the lives of the contracts; a saving of some £2.5 billion.
In the case of picture archiving and communications (PACS) systems, local savings are expected fully to offset the local costs of £684 million. Smaller savings are also expected in other areas, for example, where local NHS bodies use N3 or NHSmail to replace services for which they are currently paying. The business case for NHSmail estimated such savings at £185 million.
Mr. Clifton-Brown: To ask the Secretary of State for Health what the outcome was of capital spending against budget for (a) Avon, Wiltshire and Gloucestershire strategic health authority and (b) the Cotswold and Vale primary care trust for each of the last five years. 
| Sources: 1. Audited summarisation forms of the Avon, Wiltshire and Gloucestershire SHA. 2. Audited summarisation schedules of Cotswold and Vale PCT|
Mr. Stephen O'Brien: To ask the Secretary of State for Health what assessment she has made of the efficiency of the roll-out of the NHS IT programme to genito-urinary medicine clinics; what representations she has received on this matter; and what response she has given. 
Caroline Flint: National and local systems and services continue to be rolled out across the country in ever-increasing numbers, and every national health service location has already benefited under the national programme from delivery of software, hardware or the broadband connections that enable these to be accessed. We are on track to complete the national programme, as planned, by 2010.
In parallel with the deployment of national systems, thousands of local systems have now been delivered and serve more than 240,000 users. This includes many acute sector departmental systems supporting clinical specialties, though no systems designed specifically to support genito-urinary medicine (GUM) clinics, or other sexual health services, have yet gone live. We are not aware of any representations specifically on this matter. However, the programme's national Do Once and Share project, under the directorship of Professor Muir Gray, has engaged GUM and other sexual health clinicians, and consulted them on their future information management and technology needs. The results are being shared nationally with the support of the IM and T group of the British Association of Sexual Health and HIV.
We recognise that it is of enormous importance that systems and services delivered through the national programme should guarantee the very particular information security and confidentiality requirements of patients accessing GUM and sexual health services. Stringent security controls and safeguards have been incorporated to prevent unrestricted or uncontrolled access to personal information. Access is controlled via a unique user identity, involving a pass code and smart card, which can only be obtained on verification of identity and through a formal user registration process.
John Austin: To ask the Secretary of State for Health (1) what proportion of (a) hospital trusts, (b) primary care trusts, (c) general practitioner services and (d) intermediate care services have undertaken medicine utilisation reviews or other medicine review initiatives to ensure patients suffering from osteoporosis are prescribed the most appropriate medicine type and dosage; 
The content of the Life Check assessments at each life stage is yet to be determined and agreed, but will include the major lifestyle risk factors relevant to each life stage, such as smoking, physical activity and diet.
Mr. Drew: To ask the Secretary of State for Health pursuant to the answer of 22 June 2006, Official Report, column 2106W, on overview and scrutiny committees, why hon. Members cannot be co-opted onto OSCs. 
Ms Rosie Winterton: As stated in my previous reply, overview and scrutiny committees (OSCs) have powers set out in the Local Government Act 2000 to co-opt non-voting members onto OSCs. These co-opted members can be:
a member of a committee of the county council or another local authority, for the purposes of relevant functions of the committee in relation to the county council; or
a member of a committee of the county council, for the purposes of relevant functions of the committee in relation to another local authority.
|Next Section||Index||Home Page|